4.6 Review

Achalasia

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 8, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41572-022-00356-8

关键词

-

向作者/读者索取更多资源

Achalasia is a rare disorder of the oesophageal smooth muscle characterized by impaired relaxation of the lower oesophageal sphincter (LES) and absent or spastic contractions in the oesophageal body. It can affect individuals of all ages and both sexes, with symptoms including dysphagia, regurgitation, chest pain, and weight loss. Diagnosis involves endoscopy, high-resolution manometry, and/or barium radiography. Treatment options include pharmacotherapy, botulinum toxin injection, and surgical procedures.
Achalasia is a disorder of the oesophageal smooth muscle characterized by impaired lower oesophageal sphincter relaxation and absent or spastic oesophageal body contractions. This Primer reviews the epidemiology, pathophysiology, diagnosis and management of achalasia, as well as patient quality of life and areas for further research. Achalasia is a rare disorder of the oesophageal smooth muscle characterized by impaired relaxation of the lower oesophageal sphincter (LES) and absent or spastic contractions in the oesophageal body. The key pathophysiological mechanism is loss of inhibitory nerve function that probably results from an autoimmune attack targeting oesophageal myenteric nerves through cell-mediated and, possibly, antibody-mediated mechanisms. Achalasia incidence and prevalence increase with age, but the disorder can affect all ages and both sexes. Cardinal symptoms consist of dysphagia, regurgitation, chest pain and weight loss. Several years can pass between symptom onset and an achalasia diagnosis. Evaluation starts with endoscopy to rule out structural causes, followed by high-resolution manometry and/or barium radiography. Functional lumen imaging probe can provide complementary evidence. Achalasia subtypes have management and prognostic implications. Although symptom questionnaires are not useful for diagnosis, the Eckardt score is a simple symptom scoring scale that helps to quantify symptom response to therapy. Oral pharmacotherapy is not particularly effective. Botulinum toxin injection into the LES can temporize symptoms and function as a bridge to definitive therapy. Pneumatic dilation, per-oral endoscopic myotomy and laparoscopic Heller myotomy can provide durable symptom benefit. End-stage achalasia with a dilated, non-functioning oesophagus may require oesophagectomy or enteral feeding into the stomach. Long-term complications can, rarely, include oesophageal cancer, but surveillance recommendations have not been established.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据